Overcome Fibrosis in Kidney Disease with Epigenetics
Development of Anti-fibrotic Therapies with a Cell Line from Myofibroblasts of Fibrotic Kidneys
Tags: Tohoku University, Japan, Healthcare & Lifesciences
Kidney diseases present critical unmet medical needs, with fibrosis being a key pathology leading to renal failure, making anti-fibrotic therapies a promising approach. Researchers have found that kidney fibrosis involves the transformation of renal interstitial fibroblasts into myofibroblasts, which is reversible and crucial for understanding the disease. A novel cell line derived from myofibroblasts of mouse kidneys, named Replic cells, has been established to study the mechanisms of kidney fibrosis. These cells can be returned to their original state through epigenetic interventions, showcasing a unique feature of the research. Replic cells offer a targeted method for screening potential anti-fibrotic drugs, illustrating a practical application of this technology in the development of treatments for chronic kidney disease.
IP Type or Form Factor: Discovery & Research; Platform
TRL: Not specified
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Provider
